尧唐（上海）生物科技有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China 2024-08-27 18:30
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1 2024-08-22 18:00
First Patient Dosed in Phase I Clinical Trial of YOLT-201 2024-07-11 20:11
YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China 2024-06-19 09:00
First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH 2024-04-02 20:00
YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean 2024-03-27 20:00
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024 2024-03-13 20:00
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA 2024-03-04 20:00
YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024 2024-01-02 20:30
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM 2023-12-17 23:15
1